Company Profile

Vericel Corporation (AKA: Aastrom Biosciences Inc)
Profile last edited on: 10/23/2023      CAGE: 1G7R4      UEI: XH2PDGKKMDJ3

Business Identifier: Cellular therapies for cardiovascular diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

64 Sidney Street
Cambridge, MA 02139
   (617) 588-5555
Location: Multiple
Congr. District: 07
County: Middlesex

Public Profile

Having facilites in Ann Arbor MI and in Cambridge, MA., Vericel Corporation (NASDAQ:VCEL) was, until 2014, doing business as Aastrom Biosciences, Inc. A regenerative medicine company engaged in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases, the firm develops patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two cell therapy products in theUS: MACI® (autologous cultured chondrocytes on porcine collagen membrane) - a third generation autologous cellularized scaffold product indicated for the repair of single or multiple symptomatic, full-thickness cartilage defects of the adult knee, with or without bone involvement. Epicel® -- cultured epidermal autografts -- is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing an additional cell product. Deisgnated Ixmyelocel-T, the profuct is a multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). Vericel is also now addressing development of novel therapies for the treatment of patients with autologous (patient’s own) cells.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2006 2 NIH $853,128
Project Title: Clinical-scale Production of Osteoprogenitor Cells
2006 2 NIH $899,718
Project Title: Clinical Human Cell Production System for Broad Use
2004 1 NIH $124,154
Project Title: Bioreactor for Enhanced T-cell Based Therapy of Melanoma
2004 1 NIH $109,586
Project Title: Dendritic Cell Subset for Enhanced Cancer Vaccine
2004 2 NIH $442,555
Project Title: Automated Perfused Culture Process for Adult Stem Cells

Key People / Management

  Nick Colangelo -- President & CEO

  R Douglas Armstrong -- Chairman

  James A Cour -- Former President

  George W Dunbar -- former Chief Executive Officer, President and Director

  Michael S Durski -- CFO

  Kristin L Goltry

  Mike Halpin -- Chief Operating Officer

  Brian S Hampson -- Vice President Product Development

  Heidi Hassen -- Vice President, Human Resources

  Jon Hopper -- Chief Medical Officer

  Jonathan Hopper -- Chief Medical Officer

  Timothy M Mayleben -- former Director, Chief Executive Officer and President

  Gerard Michel -- Chief Financial Officer & Vice President of Corporate Development

  Walter C Ogier -- Marketing

  Bernhard Palsson

  Jacquelyn Fahey Sandell -- Vice President and General Counsel

  Sheldon A Schaffer -- Vice President, Corporate Development & Intellectual Property

  Alan K Smith -- President & COO

  Douglas M Smith

  Alan M Wright -- Administration